Cloudbreak gains on new drug's progress

Cloudbreak Pharma Inc 2592.HK gains 7.5% to HK$8.60; set for biggest one-day pct drop since November 28

Ophthalmic therapies developer's unit schedules to meet with U.S. FDA on Wednesday at End-of-Phase 2 meeting to discuss potential Phase 3 clinical trial development, New Drug Application requirements for CBT-004 - drug used to treat vascularised pinguecula

Co says it considers meeting to be significant milestone in CBT-004's development

Since market debut on July 3, stock falls 15.2%